Genome editing: the breakthrough technology for inherited retinal disease?
Files in This Item:
|ExpOpBiolTher_AcceptedManuscript.pdf||3.08 MB||Adobe PDF||Download|
|Title:||Genome editing: the breakthrough technology for inherited retinal disease?||Authors:||Smith, Andrew J.; Carter, Stephen P.; Kennedy, Breandán||Permanent link:||http://hdl.handle.net/10197/10555||Date:||11-Jul-2017||Online since:||2019-05-21T07:47:15Z||Abstract:||Introduction: Genetic alterations resulting in a dysfunctional retinal pigment epithelium and/or degenerating photoreceptors cause impaired vision. These juxtaposed cells in the retina of the posterior eye are crucial for the visual cycle or phototransduction. Deficits in these biochemical processes perturb neural processing of images capturing the external environment. Notably, there is a distinct lack of clinically approved pharmacological, cell- or gene-based therapies for inherited retinal disease. Gene editing technologies are rapidly advancing as a realistic therapeutic option. Areas Covered: Recent discovery of endonuclease-mediated gene editing technologies has culminated in a surge of investigations into their therapeutic potential. In this review, the authors discuss gene editing technologies and their applicability in treating inherited retinal diseases, the limitations of the technology and the research obstacles to overcome before editing a patient’s genome becomes a viable treatment option. Expert Opinion: The ability to strategically edit a patient’s genome constitutes a treatment revolution. However, concerns remain over the safety and efficacy of either transplanting iPSC-derived retinal cells following ex vivo gene editing, or with direct gene editing in vivo. Ultimately, further refinements to improve efficacy and safety profiles are paramount for gene editing to emerge as a widely available treatment option.||Funding Details:||Health Research Board
Irish Research Council
|metadata.dc.description.othersponsorship:||Fighting Blindness||Type of material:||Journal Article||Publisher:||Taylor & Francis||Journal:||Expert Opinion on Biological Therapy||Volume:||17||Issue:||10||Start page:||1245||End page:||1254||Copyright (published version):||2017 Taylor & Francis||Keywords:||Retina; Photoreceptor; Retinal pigment epithelium; Inherited retinal disease; Gene editing; CRISPR||DOI:||10.1080/14712598.2017.1347629||Language:||en||Status of Item:||Peer reviewed|
|Appears in Collections:||Biomolecular and Biomedical Science Research Collection|
Show full item record
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. For other possible restrictions on use please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.